WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
WuXi AppTec, founded in December, 2000 and headquartered in Wuxi, is Ge Li. The founder is Ge Li. Listed on the HKEX on December 13, 2018, the company's major shareholders are HKSCC Nominees Ltd, G&C VI Ltd and Summer Bloom Investments (I) PTE. Ltd. Rivals that have direct and indirect competition with WuXi AppTec include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Russian finance minister says West creates artificial obstacles for Russia to repay public debt
The maximum payment limit of employee medical insurance in Shanghai in 2022 was raised to 590000 yuan
The private placement market is full of chaos, and the regulators' sword is intended to support the good and limit the bad
Cro plate fell, and Wuxi apptec fell nearly 10%
2022 China AI Health 30 Report
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
The trading limit of AVIC electronics and AVIC electromechanical resumed
The port sector continued to strengthen and Guangzhou port rose by the daily limit
Runfeng shares: exchange rate changes have little impact on the company's performance
Deputy Secretary General of China Cement Association: it is expected that the industry will usher in a turnaround in the second quarter
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Tesla unveiled a new giant 360mwh Megapack energy storage project
The steel plate rose and Jinling mining rose by the limit
Capital group, an asset management institution, launched ETF products for the first time: buying Chinese stocks such as Guizhou Maotai, Yaoming biology and meituan
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
Traditional Chinese medicine stocks rose and strengthened, and Dali pharmaceutical touched the daily limit
New products are popular, pension finance plays a characteristic card
Tianci materials: the net profit in the first two months increased by about 470% year-on-year
Tencent clarified the rumor source of "heavy hammer". A snowball user has voluntarily cancelled his account